These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 1398234)

  • 1. Antiviral effect of prolonged intermittent lymphoblastoid alpha interferon treatment in chronic hepatitis B.
    Janssen HL; Berk L; Schalm SW; Heijtink RA; Hess G; Rossol S; Meyer zum Buschenfelde KH; Chamuleau RA; Jansen PL; Reesink HW
    Gut; 1992 Aug; 33(8):1094-8. PubMed ID: 1398234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of chronic hepatitis B (HBeAg-HBV DNA-positive) with lymphoblastoid alpha interferon with or without corticosteroids: short- and long-term follow-up.
    Zavaglia C; Bottelli R; Bellati G; Asti L; Mondazzi L; Iamoni G; Zanetti A; Tanzi E; Fesce E; Gelosa F; Maggi G; Ideo G
    Ital J Gastroenterol; 1996; 28(6):324-31. PubMed ID: 8891847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short report: prednisolone withdrawal followed by lymphoblastoid interferon in the therapy of adult patients with presumed childhood-acquired chronic hepatitis B virus infection.
    Brook MG; Main J; Yap I; Chan G; Karayiannis P; Crossey M; Thomas HC
    Aliment Pharmacol Ther; 1993 Jun; 7(3):331-6. PubMed ID: 8364139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP).
    Janssen HL; Gerken G; Carreño V; Marcellin P; Naoumov NV; Craxi A; Ring-Larsen H; Kitis G; van Hattum J; de Vries RA; Michielsen PP; ten Kate FJ; Hop WC; Heijtink RA; Honkoop P; Schalm SW
    Hepatology; 1999 Jul; 30(1):238-43. PubMed ID: 10385662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group.
    Krogsgaard K; Marcellin P; Trepo C; Berthelot P; Sanchez-Tapias JM; Bassendine M; Tran A; Ouzan D; Ring-Larsen H; Lindberg J; Enriquez J; Benhamou JP; Bindslev N
    J Hepatol; 1996 Dec; 25(6):803-13. PubMed ID: 9007706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of quantitative assays for hepatitis B e antigen and IgM antibody to hepatitis B core antigen to monitor therapy in chronic hepatitis B.
    Hayashi PH; Beames MP; Kuhns MC; Hoofnagle JH; Di Bisceglie AM
    Am J Gastroenterol; 1996 Nov; 91(11):2323-8. PubMed ID: 8931411
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective randomized controlled trial of sequential treatment with corticoids and alpha-interferon versus treatment with interferon alone in patients with chronic active hepatitis B.
    Niederau C; Heintges T; Niederau M; Stremmel W; Strohmeyer G
    Eur J Med; 1992 Nov; 1(7):396-402. PubMed ID: 1341478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated courses of alpha-interferon for treatment of chronic hepatitis type B.
    Janssen HL; Schalm SW; Berk L; de Man RA; Heijtink RA
    J Hepatol; 1993; 17 Suppl 3():S47-51. PubMed ID: 8509639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs.
    Ouzan D; Pénaranda G; Joly H; Khiri H; Pironti A; Halfon P
    J Clin Virol; 2013 Dec; 58(4):713-7. PubMed ID: 24183313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peginterferon-α2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study.
    Huang Z; Deng H; Zhao Q; Zheng Y; Peng L; Lin C; Zhao Z; Gao Z
    Eur J Gastroenterol Hepatol; 2013 Oct; 25(10):1165-9. PubMed ID: 23571612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomized, placebo-controlled trial.
    Janssen HL; Berk L; Heijtink RA; ten Kate FJ; Schalm SW
    Hepatology; 1993 Mar; 17(3):383-8. PubMed ID: 8444411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prolonged duration of the routine pegylated-interferon alfa-2a therapy produces superior virological response in HBeAg-positive chronic hepatitis B patients: a single-center cohort study].
    Zhu YY; Wu YL; Chen J; Zheng Q; Dong J; Jiang JJ
    Zhonghua Gan Zang Bing Za Zhi; 2012 Oct; 20(10):737-41. PubMed ID: 23207332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
    Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
    Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trial.
    Berk L; Schalm SW; de Man RA; Heytink RA; Berthelot P; Brechot C; Boboc B; Degos F; Marcellin P; Benhamou JP
    J Hepatol; 1992 Mar; 14(2-3):305-9. PubMed ID: 1500694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The value of quantitative measurement of HBeAg and HBsAg before interferon-alpha treatment of chronic hepatitis B in children.
    Burczynska B; Madalinski K; Pawlowska J; Woynarowski M; Socha J; Gerlich WH; Willems WR; Wozniewicz B; Stachowski J
    J Hepatol; 1994 Dec; 21(6):1097-102. PubMed ID: 7699234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intrahepatic response markers in chronic hepatitis B patients treated with peginterferon alpha-2a and adefovir.
    Takkenberg B; Terpstra V; Zaaijer H; Weegink C; Dijkgraaf M; Jansen P; Beld M; Reesink H
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1527-35. PubMed ID: 21557773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 208-week sequential therapy with telbivudine and entecavir in HBeAg-positive chronic hepatitis B patients with suboptimal responses to 24 weeks of Peg-IFNα-2a therapy: An open-labelled, randomized, controlled, "real-life" trial.
    Luo XD; Chen XF; Zhou Y; Chen XP
    J Viral Hepat; 2017 Nov; 24 Suppl 1():36-42. PubMed ID: 29082651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
    Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
    Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged (6 months) treatment of chronic hepatitis B virus infection with recombinant leukocyte A interferon.
    Carreño V; Porres JC; Mora I; Bartolomé J; Bas C; Gutiez J; Cortés J; Hernández Guio C
    Liver; 1987 Dec; 7(6):325-32. PubMed ID: 3437794
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.